Orthobiologics

The limited market release of Tempest Allograft Bone Matrix marks Spine Wave's entry into the spinal biologics market....

The product expands Aziyo's regenerative medicine portfolio and leverages proprietary processing to protect and preserve native bone cells....

Bioventus received FDA 510(k) clearance to market SIGNAFUSE® Bioactive Bone Graft in a strip format. The strips consist of 55%...

STIMULAN is the first calcium matrix to receive European approval as an antibiotic carrier for use in bone and soft...

Osteo3 ZP Putty combines best-in-class bone repair with intraoperative ease-of-use for spine and trauma bone grafting applications....

Enrollment of the FORTIFY study on CERAMENT G has been completed, with 198 subjects enrolled. BONESUPPORT expects to submit a...

BONESUPPORT's bone graft substitutes are based on the patented CERAMENT technology platform. Direct sales commence in July 2020....

Results show that elderly patients undergoing non-instrumented fusion achieve statistically significantly higher fusion rates with i-FACTOR vs. allograft....

The JTA-004 Phase III study is approved in five of seven territories. These are the first patients treated after resumption...

Carmell will begin enrolling in a pivotal clinical program for Plasma-based Bioactive Material used in long-bone fractures as an adjunctive...